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Heart failure (HF) is associated with substantial clin-
ical burden and economic costs worldwide. The dis-
ease is particularly prevalent in elderly individuals, in 
whom the incidence and associated costs are projected 
to double over the next 20 years1,2. Economic costs 
associated with the management of patients with HF 
is estimated at >US$30 billion annually in the USA 
alone, and accounts for roughly 2–3% of total health-
care spending globally3,4. Despite these enormous costs, 
mortality from HF remains high. Death from HF within 
5 years of diagnosis is common despite current opti-
mal medical therapy. Mortality and rehospitalization 
within 60–90 days after discharge from hospital can 
be as high as 15% and 35%, respectively5. These event 
rates have largely not changed over the past 15 years, 
despite implementation of evidence-based therapy5. 
HF rehospitalization rates also remain high, with care 
typically focused on symptomatic relief. Patients with 
HF are often designated as having either reduced ejec-
tion fraction (HFrEF), or preserved ejection fraction 
(HFpEF). Patients with HFpEF also have poor prognosis 
after the first diagnosis6. Regardless of the HF aetiology, 
novel treatments that improve intrinsic cardiac function 
remain elusive.
Advances in the treatment of ischaemic and valvu-
lar heart disease have clearly improved patient sur-
vival. The residual cardiac dysfunction and associated 
comorbid ities, however, have led, in the long-term, to the 
development of HF with attendant poor quality of life. 
Commonly prescribed HF medications, although benefi-
cial in promoting some symptom relief, often do not fully 
address the underlying causes of progressive left ven-
tricular dysfunction7. Most standard-of-care pharmaco-
logical approaches to HF act by reducing workload on the 
failing heart and, in doing so, attempt to rebalance energy 
supply and energy demand, albeit to a lower level (FIG. 1). 
Hallmarks of current therapies include modulation of 
neurohormonal abnormalities, unloading the heart 
(that is, vasodilatation), and/or reducing the heart rate 
— all important determinants of reducing myo cardial 
oxygen consumption8. β-Blockers, ivabradine, and antag-
onism of the renin–angiotensin–aldosterone system all 
act in concert to reduce myocardial energy requirements 
and attenuate or prevent further adverse cardiac remodel-
ling. Although these therapies have improved survival in 
patients with chronic ambulatory HFrEF over the past 
2–3 decades, death and poor quality of life continue to 
adversely affect this ever-increasing patient population. 
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Abstract | Heart failure is a pressing worldwide public-health problem with millions of patients 
having worsening heart failure. Despite all the available therapies, the condition carries a very 
poor prognosis. Existing therapies provide symptomatic and clinical benefit, but do not fully 
address molecular abnormalities that occur in cardiomyocytes. This shortcoming is particularly 
important given that most patients with heart failure have viable dysfunctional myocardium, 
in which an improvement or normalization of function might be possible. Although the 
pathophysiology of heart failure is complex, mitochondrial dysfunction seems to be an important 
target for therapy to improve cardiac function directly. Mitochondrial abnormalities include 
impaired mitochondrial electron transport chain activity, increased formation of reactive oxygen 
species, shifted metabolic substrate utilization, aberrant mitochondrial dynamics, and altered ion 
homeostasis. In this Consensus Statement, insights into the mechanisms of mitochondrial 
dysfunction in heart failure are presented, along with an overview of emerging treatments 
with the potential to improve the function of the failing heart by targeting mitochondria.
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This unmet need is probably not going to be met by drugs 
that modulate neurohormonal abnormalities and lower 
heart rates, because further intervention along these 
axes is likely to be counterproductive as hypotension 
and bradycardia become limiting factors. The search 
for more effective and complementary therapy for this 
patient population must be focused on improving the 
intrinsic function of the viable, but dysfunctional, cardiac 
unit — the cardiomyocytes3,9. The novel therapy must be 
haemodynamically neutral (no decrease in blood pres-
sure or heart rate) and must target the myocardium as the 
centrepiece of the therapeutic intervention10.
The vast majority of phase III trials in patients with 
HF conducted in the past decade have been negative, 
arguably for the same reasons discussed above11,12. 
Furthermore, a relative underinvestment in cardiovascu-
lar drug development, as well as strategic abandonment 
by pharmaceutical companies of new therapies for which 
the risks are perceived to be higher than the rewards, have 
also contributed to slow development of drugs for HF13. 
Moreover, the development of effective therapies for 
HFpEF is imperative to treat this patient population, but 
the variability in HFpEF phenotypes (such as age, and the 
presence of diabetes mellitus or hypertension), and 
the difficulty in establishing reliable preclinical models 
of HFpEF, also hinder progress. Despite these obstacles, 
ample opportunity exists to improve HF treatments, 
prov ided the focus is directed towards cardiomyocytes 
and their intrinsic function.
A roundtable meeting was held in Stresa, Italy on 
23 October 2015 to discuss the multifaceted problem 
of insufficient energy production in HF, and the role 
it has in progressive left ventricular dysfunction. This 
meeting was attended by academics, clinicians, and 
representatives from the pharmaceutical industry. The 
meeting focused on mitochondrial dysfunction as the 
source of energy deprivation in HF, and how correction 
of mitochondrial dysfunction using emerging novel 
therapies might lead to functional improvement of the 
HF phenotype. This Consensus Statement summarizes 
the findings from that roundtable discussion.
Bioenergetics of the beating heart
Aristotle considered the heart to be the body’s fur-
nace, radiating energy in the form of heat14. Given the 
astounding energetic cost of cardiac function, this con-
cept is not so far from the truth. Humans produce and 
consume roughly their body weight in ATP (about 65 kg) 
every single day15. The heart accounts for only ~0.5% of 
body weight, but is responsible for roughly 8% of ATP 
consumption. This high energy flux is dynamic: the 
heart stores only enough energy to support pumping 
for a few heart beats, turning over the entire metabo-
lite pool approximately every 10 s even at resting heart 
rates16. As the most metabolically active organ in the 
body, the heart possesses the highest content of mito-
chondria of any tissue. Mitochondria comprise 25–30% 
of cell volume across mammalian species17,18, with only 
the myofilaments being more densely packed within 
cardiac myocytes. The high mitochondrial content of 
cardiomyocytes is needed to meet the enormous energy 
requirement for contraction and relaxation (which is 
also an active process). About 90% of cellular ATP 
is util ized to support the contraction–relaxation cycle 
within the myocardium19. ATP-dependent release of 
actin from myosin is required for both contraction 
(as myosin heads cycle through cross-bridges with actin) 
and relaxation. Cellular sequestration of calcium back 
into the sarcoplasmic reticulum during diastole also 
requires a tremendous amount of ATP. Cells sustain 
the energy requirements necessary to support cardiac 
function through remarkable metabolic supply–demand 
matching20,21 (FIG. 1). Bioenergetic homeostasis is accom-
plished almost exclusively through an ‘energy grid’ com-
prised of a mitochondrial network and their associated 
phosphate- transfer couples. Cardiac mitochondria 
must operate at high efficiency levels to respond instan-
taneously to the energetic needs of contractile units, 
a demand that is ever-changing and necessitated by the 
body’s dynamic requirements for oxygen-bearing blood.
Myocardial energy requirements are more pro-
nounced during physical activity, when demands for 
energy increase to maintain cardiac function commensur-
ate with the needs of the body. However, other mitochon-
drial abnormalities besides energy deprivation during 
physical activity can contribute to the pathologies seen 
in patients with HF. Mitochondrial abnormalities in HF 
are not only a question of reduced capacity to generate 
ATP (even though that capacity is reduced at rest in HF 
compared with resting normal), but can also be directly 
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linked to cardiomyocyte injury and death and, therefore, 
to disease progression. Abnormal mitochondria are a 
major source of reactive oxygen species (ROS) produc-
tion, which can induce cellular damage. Abnormal mito-
chondria can promote programmed cell death through 
the release of cytochrome c into the cytosolic compart-
ment and activation of caspases. Therefore, mitochon-
dria directly influence ongoing cell injury and death. 
Mitochondrial abnormalities have also been implicated 
in aberrant cellular calcium homeostasis, vascular smooth 
muscle pathology, myofibrillar disruption, and altered 
cell differentiation, all important issues in cardiovascular 
 disease, including HF.
Mitochondria in cardiomyocytes
Mitochondria are primarily located within subsarcolem-
mal, perinuclear, and intrafibrillar regions of the cardio-
myocyte. Although they are symbiotic partners with the 
other cellular compartments, mitochondria are in many 
ways discrete entities. Mitochondrial dynamics in the 
form of fission, fusion, and autophagy are highly regu-
lated processes that are essential for energy production 
and structural integrity of the organelles22–29. Altered 
mitochondrial biogenesis, fragmentation, and hyper-
plasia have been observed in studies of human30 and 
animal models31,32 of HF. These effects seem to be caused 
by altered expression of proteins that regulate mitochon-
drial dynamics33. As many of these factors are ‘master 
regulators’ of mitochondrial metabolism, these changes 
might be directly related to the decreased  capacity to 
 oxidize fatty acid substrates often seen in HF34,35.
Mitochondria have their own DNA (mtDNA) and a 
genetic code that is distinct from the host-cell nuclear 
DNA. mtDNA is circular in shape, analogous to DNA 
found in lower organisms, and a primitive fingerprint 
leftover from bacterial origin. Evolutionary selection 
pressures have led to mitochondria ‘outsourcing’ almost 
all their protein-making needs to their cellular hosts. The 
overwhelming majority (>99%) of mitochondrial pro-
teins come from nuclear-encoded DNA. These proteins 
are synthesized via cellular protein synthesis machinery, 
and are actively imported into mitochondria through 
mitochondrial membrane transporters36. mtDNA 
encodes 13 protein subunits found within three of the 
Figure 1 | Energy supply–demand matching in health and heart failure. The delicate balance between cardiac demands 
for energy and supply of energy is tipped in heart failure, in which energy supply cannot match demand. Next-generation 
therapeutics can improve on existing standard-of-care therapies by bolstering mitochondrial energy production. 
ACE, angiotensin-converting enzyme; ARB, angiotensin II-receptor blocker; ETC, electron transport chain; HFpEF, heart 
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ROS, reactive oxygen species.
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electron transport protein complexes, and a handful 
of ribosomal and transfer RNAs37. These proteins are 
made in specialized ribosomes or ‘mitoribosomes’, 
which are physically attached to the  mitochondrial 
inner membrane38.
Many inherited familial cardiomyopathies (both adult 
and paediatric) are associated with mtDNA mutations39. 
In humans, mitochondria are maternally inherited40, 
owing to high mitochondrial density in the egg and the 
active degradation of mitochondria in the sperm during 
fertilization41. The proximity of mtDNA to sites of mito-
chondrial ROS generation, poor repair mechanisms, and 
a lack of protective histones combine to make mtDNA 
particularly susceptible to oxidative injury and mutation.
Mitochondrial genetics contribute to cardiomyo-
pathies by expressing mutant proteins that influence 
energy homeostasis. With 1,000–10,000 genes per mito-
chondria (polyploidy), mitochondrial genetics operate 
on population-based (instead of Mendelian) principles37. 
Mutated mtDNA is found alongside nonmutated copies, 
leading to mitochondrial ‘heteroplasmy’. The extent of 
heteroplasmy in mutated mtDNA influences the sus-
ceptibility to inherited mitochondrial disease42. Mutated 
mtDNA can be found in 1 in 200 individuals, a fre-
quency that is 20-fold higher than the incidence of mito-
chondrial disease. This mismatch indicates that healthy 
individ uals often harbour mutated mtDNA that has no 
observable phenotypic consequences until a certain 
mutation threshold is reached37. Although very early in 
preclinical development, various innovative approaches 
to reduce the extent of heteroplasmy using genome 
editing might ultimately lead to effective therapy for 
HF caused by genetic mitochondrial disease43–45. Given 
that mitochondrial abnormalities, such as increased 
ROS production, altered mitochondrial energetics, and 
impaired mitochondrial ion homeostasis, are observed 
in genetic mitochondrial diseases as well as HF, innova-
tive approaches that target mitochondrial dysfunction 
might share efficacy across these diseases.
Heart failure is a bioenergetic disease
The ‘myocardial power grid’ consists of mitochondrial 
ATP supply that transfers energy throughout the cell 
along intracellular phosphotransfer buffering systems 
(FIG. 2). Mitochondria utilize carbon sources from food 
substrates, which are catabolized and passed through the 
Krebs cycle and are then channelled through a series of 
redox reactions along the inner mitochondrial mem-
brane. The oxidation of these substrates creates a pro-
ton electrochemical gradient, predominantly in the form 
of mitochondrial membrane potential (ΔΨm)46. Protons 
that re-enter the mitochondrial matrix through com-
plex V (mitochondrial ATP synthase) liberate energy 
that phosphorylates ADP, regenerating ATP. Newly 
synthesized ATP is rapidly transferred out of mitochon-
dria and energy is subsequently distributed throughout 
the cell via reversible phosphate exchange networks, 
primarily catalysed by creatine kinase and adenylate 
 kinase-associated reactions16,47.
The evidence that HF involves impaired cellular 
energy production and transfer is considerable (TABLE 1). 
Among studies that have directly examined energetics 
in human HF, all but three noted some form of bioener-
getic impairment in the failing heart. This decrement in 
bioenergetics is reflected by a decrease in cellular ATP, 
phosphocreatine (PCr), or the PCr/ATP ratio. Impaired 
bioenergetics affect patients with HFrEF and those with 
HFpEF (TABLE 1).
Although it is difficult to tell from the heterogeneous 
patient population included in TABLE 1, the progression 
to HF is likely to be associated with a gradual decline in 
bioenergetic reserve capacity that ultimately reaches a 
critical threshold, after which endogenous mechanisms 
can no longer compensate for faltering energy supply48. 
Attempts to improve bioenergetics in HF tend to focus 
on mitochondrial energy production as a target, because 
direct augmentation of myocardial creatine with oral 
creatine supplementation is thwarted by a decreased 
capacity to transport creatine into the failing cardio-
myocytes49. Skeletal muscles also show mitochondrial 
dysfunction in HF, contributing to the exercise intoler-
ance that characterizes the HF state50. Abnormal mito-
chondrial function has also been reported in patients 
with renal insufficiency51, and in patients with insulin 
resistance52. Given that patients with HF often manifest 
both renal insufficiency and insulin resistance, treating 
Figure 2 | Impaired mitochondrial capacity and function in heart failure. Decreased capacity of mitochondria to 
generate and transfer energy within heart cells results in energy deficits, which influences all cellular processes that 
require energy, most notably the processes of contraction and relaxation.
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mitochondrial dysfunction in HF derives benefits that 
go beyond improving cardiac function (FIG. 3).
Several interventions are currently being tested in 
clinical trials to stimulate mitochondrial biogenesis 
in HF. These include epicatechin and resveratrol, which 
are naturally-occurring polyphenols found in foods such 
as red wine, green tea, and dark chocolate. Preclinical 
HF models suggest that these molecules are biologically 
active53–55, and some success in improving cardiac func-
tion has been reported in small trials of patients with 
myocardial  infarction56. Larger trials in patients with HF 
are required.
Mitochondrial substrate selectivity
Substrate utilization in the failing heart has been exten-
sively reviewed previously57–60. Overall, altered sub-
strate metabolism seems to be centrally involved in HF, 
although the direction of the metabolic alterations is com-
plex and is likely to depend on the particular stage of HF 
progression and differences in the availability of  substrate 
(whether the heart is in a ‘fed’ or ‘fasted’ state)58,59.
The heart utilizes different substrates simultaneously 
to produce energy. Mitochondrial fatty acid oxidation 
(FAO) is the predominate substrate used in the healthy 
adult human heart, being responsible for 60–80% of 
Table 1 | Bioenergetic changes in human heart failure
Patient characteristics (n) ATP PCr PCr/ATP Notes
NYHA class II (29), class III (8)228 NR NR ↓ Decrease in PCr/ATP ratio in patients with HFpEF
NYHA class I (10), class III (8), class IV (1)229 NR NR ↓ Decrease in PCr/ATP ratio in HCM correlated with presence of fibrotic 
areas in myocardium of left ventricle
LVH (20); LVH and CHF (10); no LVH (10)230 ↓ ↓ ↓ Decrease in ATP flux through CK; 30% decrease in PCr/ATP ratio
NYHA class I (1), class II (7), class III (7),  
class III–IV (1), class IV (1)231
↓ ↓ NR —
HCM gene mutations in MHC7 (16), TNNT2 (8), 
or MYBPC2 (7) (31)232
NR NR ↓ 30% reduction in patients with HCM compared with controls; reduction 
similar in all groups
HHD (NYHA class 0 [10]) = = ↓ • No change in ATP in AS or HHD; 35% decrease in ATP in DCM
• 28% decrease in PCr in AS, 51% in DCM, no change in HHD
• 25% decrease in PCr/ATP ratio in HHDAS (NYHA class II [7], class III [3]) = ↓ NR
DCM (NYHA class II [1], class III [9])233 ↓ ↓ NR
AS (10); five followed up234 NR NR ↓ Decrease in PCr/ATP before aortic valve repair
HHD (11)235 NR NR ↓ —
Chronic mitral regurgitation (22)236 NR NR ↓ —
HCM (14)237 NR NR ↓ —
DCM (43 total; 6 restrictive cardiomyopathy, 10 
normal systolic and diastolic function; 24 cold 
preserved from transplantations)238
↓ NR NR Decrease in ATP in DCM
AI (9; NYHA class average 2.44) or 
AS (13; NYHA class average 2.77)239
NR NR ↓ • Significant reduction in PCr/ATP ratio in patients with AS; trend 
towards a reduction in patients with AI
• Significant decrease in PCr/ATP ratio for all patients in NYHA class III, 
but not those in class I or II
DCM (23; NYHA class average 2.7)240 NR NR ↓ —
AS (41)241 ↓ ↓ NR —
Severe AS (27)242 NR NR ↓ Hand-grip strength tests (marker of cardiac health) employed in patients
HCM (19)243 NR NR ↓ —
DCM and CHF (NYHA class I [1], class II [3], 
class III [4])244
NR NR = No change with dobutamine infusion
DCM (9), HCM (8)245 NR NR ↓ Decreased PCr/ATP ratio in HCM, but not DCM
CAD (14), DCM (19 total; NYHA class II [4], 
class III [4], class II–III [7], class III–IV [4])246
NR NR ↓ • Decreased PCr/ATP ratio in DCM
• Trend for decreased PCr/ATP ratio in CAD
• Relationship exists between severity of HF and decrease in PCr/ATP ratio
DCM (19), ICM (11)247 = NR NR • No change in ATP levels in DCM biopsies
• Lower ATP levels in ICM, but not significantly different
Aortic valve disease (6), AI (8)248 NR NR ↓ Decreased PCr/ATP ratio in patients being treated for heart failure
DCM (20)249 NR NR ↓ —
DCM (6), severe LVH (6), mild LVH (5)250 NR NR = No change in PCr/ATP ratio in LVH or DCM
AI, aortic insufficiency; AS, aortic stenosis; CAD, coronary artery disease; CHF, congestive heart failure; CK, creatine kinase; DCM, dilated cardiomyopathy; 
HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; HHD; hypertensive heart disease; ICM, insertable cardiac monitor; 
LVH, left ventricular hypertrophy; NR, not reported; PCr, phosphocreatine.
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cardiac ATP production, followed by lesser contributions 
from glucose, lactate, and ketone bodies61. However, the 
heart can shift the relative contribution of these substrates 
in an effort to adapt to varying physiological conditions. 
Under conditions of low oxygen content, such as ischae-
mia and HF, ATP content is thought to decrease by as 
much as 40%3. In HF, fatty acid oxidation and the oxid-
ative  capacity of the mitochondria decline, and can no 
longer maintain sufficient levels of ATP, especially during 
conditions of increased cardiac workload such as exercise. 
The failing heart shifts its predominant fuel source from 
mitochondrial FAO toward glycolytic pathways. This 
switch is most apparent in late and end-stage HF57, and 
is 30% more energetically efficient in the failing heart, 
because more ATP is produced per mole of oxygen dur-
ing carbohydrate oxidation62. Numerous studies investi-
gating FAO, glucose oxidation, and (to a lesser extent) 
ketone body oxidation have aimed to establish a meta-
bolic pheno type, underlying molecular mechanisms, and 
potential therapeutic targets of the failing heart.
The reduction in fatty acid uptake and FAO that 
occurs during HF might be owing to dysregulated mol-
ecu lar mechanisms responsible for fatty acid metabolism. 
For example, the level of peroxisome prolifer ator-
activated receptor-α (PPARα), a transcription factor 
highly expressed in the heart and responsible for fatty 
acid transport into the mitochondria and peroxisomes, 
has been reported to be downregulated in both animal 
models and humans with HF63,64. Similarly, tissue from 
animals and humans with HF has reduced activity of the 
transcription factor responsible for mitochondrial bio-
genesis, PPAR-γ co-activator (PGC)-1α64,65. Because these 
transcription factors have a critical role in the regulation 
of cardiac mitochondrial energy production, these data 
suggest that decreased PPARα and PGC-1α activity might 
be an important precursor leading to impaired FAO dur-
ing HF. Therefore, further inhibition of FAO to increase 
glycolytic flux via PPARα and/or PGC-1α is a plausible 
therapeutic target. Small-molecule regulators of PGC-1α 
are needed, and animal models overexpressing the tran-
scription factor are inherently problematic, ostensibly 
owing to increased mitochondrial biogenesis-induced 
cardiomyopathy66. Similarly, PPARα antagonists in 
animal models of HF have yielded inconclusive data67, 
whereas clinical PPARα ligands are reportedly safe, but 
their efficacy in a HF population is currently unknown61. 
Although the safety of PPARα ligands is promising, fur-
ther evidence demonstrating their efficacy in both animal 
models and humans with HF is needed.
Levels of circulating free fatty acids might be higher 
in the failing heart than under healthy conditions owing 
to hormonal stimulation. The rise in serum catechola-
mine levels increases plasma free fatty acid concentra-
tions, and subsequently stimulates FAO68. As a result, 
reducing the availability of circulating free fatty acids 
via transient adrenergic antagonists might be a viable 
therapy to inhibit FAO and increase glycolytic ATP 
prod uction. Traditionally, β-adrenergic receptor antago-
nists are used in HF owing to their negative ionotropic 
effects that reduce cardiac workload and spare oxygen 
by decreasing sympathetic activity68. Many, such as 
carvedilol, have been clinically shown to lessen infarct 
size after ischaemia by decreasing sympathetic activity, 
 followed by inhib ition of mitochondrial fatty acid uptake 
and increased glucose oxidation69.
Malonyl-CoA endogenously regulates fatty acid 
concentrations by controlling the activity of carnitine 
O-palmitoyltransferase (CPT) 1, a rate-limiting enzyme 
in mitochondrial fatty acid uptake68. When intracellular 
levels of malonyl-CoA are increased, CPT1 is inhibited 
and mitochondrial fatty acid uptake is stopped70. The 
intracellular concentration of malonyl-CoA is depend-
ent on the balance between its synthesis via acetyl-CoA 
carboxylase and degradation via malonyl-CoA decar-
boxylase. Therefore, the upregulation of acetyl-CoA 
carboxyl ase or inhibition of malonyl-CoA decarboxyl-
ase would increase intracellular malonyl-CoA levels, and 
prevent mitochondrial uptake of free fatty acids to reduce 
FAO. As expected, inhibiting malonyl-CoA decarboxyl-
ase in animal models has reportedly improved cardiac 
function after ischaemia, reduced cardiac FAO, and 
increased glyco lytic flux71,72. Studies of malonyl-CoA 
decarboxylase inhibitors in patients with HF are needed.
Trends in glucose oxidation across the spectrum of 
HF are more variable, particularly among animal models 
of HF58. Compensatory substrate switching towards glu-
cose use has been observed in both animal models and 
humans59, with a higher contribution coming from glyco-
lysis. Stimulating mitochondrial glucose oxidation, either 
directly or by inhibiting fatty acid catabolism, has been 
suggested as a viable therapeutic strategy to compensate 
for the energetically ‘starved’ failing heart59.
Ketone body metabolism also seems to be altered in 
HF. Ketones are formed in the liver via fatty acid metabo-
lism, and provide a small substrate pool for oxidation 
within the myocardium. In conditions such as diabetes or 
starvation, ketone catabolism is upregulated in response 
to lowered insulin availability and higher fatty acid lev-
els57,73. Studies have reported increased ketone utiliza-
tion in the severely failing heart in humans73,74. Further 
research is needed to understand the role of ketone 
oxidation in the failing myocardium, and to determine 
Figure 3 | Mitochondrial contribution across multifaceted symptoms of heart 
failure. Aberrant mitochondrial energy production is involved in many symptoms 
commonly found in patients with heart failure, including skeletal muscle dysfunction 
and renal pathologies. LV, left ventricular.
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whether targeting ketone metabolism is a plausible 
 therapy to improve energetics in HF.
Novel insights into the regulation of metabolic sub-
strate demand in the heart have been provided through 
studies of microRNAs and acetylation of mitochondrial 
lysine residues. Alterations in microRNA levels through 
any number of upregulation and downregulation events 
can alter substrate utilization in the heart75. Alterations 
in protein levels modulated by microRNA expression 
have been proposed to have important implications 
for glycoly sis, β-oxidation, ketone metabolism, the 
Krebs cycle, and the electron transport chain (ETC)75. 
For example, increased levels of ROS can alter calcium 
handl ing in HF by modifying microRNA that leads 
to inhibition of sarcoplasmic/endoplasmic reticulum 
calcium ATPase (SERCA) 2a transcription75. Post-
translational modification via lysine acetylation has been 
suggested to have an important role in metabolic enzyme 
regulation in the mitochondria59.
Overactivation of the SNS
As all substrates converge on mitochondria, understand-
ing the specific abnormalities that occur in HF is central 
to the development of new treatments. ROS production 
increases in many aetiologies of HF, a phenomenon that 
might be directly related to increased sympathetic nerv-
ous system (SNS) tone76. Sustained sympathetic drive 
and chronically elevated circulating catecholamines — 
processes that are normally transient to mediate acute 
increases in cardiac output — are commonly observed 
in patients with HF (particularly HFrEF)77,78. Chronic 
stimulation of β-adrenergic receptors has been directly 
linked to mitochondrial ROS production through adren-
ergic receptor-mediated second messenger signalling79,80. 
ROS-mediated initiation of mitochondria-dependent cell 
death cascades has been repeatedly observed after chronic 
sympathetic activation, leading to overall declines in mito-
chondrial function81–86. These processes can be amplified 
by the formation of aminochromes, catecholamine metab-
olites known to impair mitochondrial redox balance87. 
Attenuation of HF pathology with β-blockers and renin–
angiotensin–aldosterone antagonism has resulted in sub-
stantial clinical improvements88, and is likely to relieve 
some of the mitochondrial dysfunction that accompanies 
increased sympathetic tone. The capacity to complement 
these existing background therapies with compounds that 
directly target mitochondrial dysfunction is a potentially 
promising novel paradigm (FIG. 1).
Increased ROS production
Cellular ROS production occurs when ROS formation 
outpaces or exhausts compensatory signals and over-
whelms endogenous scavenging systems89–91. ROS are 
produced at several different sites within cells, both within 
and outside of mitochondria (reviewed in detail previ-
ously92–95). Mitochondrial ROS production occurs at vari-
ous sites along the inner mitochondrial membrane as well 
as in the mitochondrial matrix by components of the ETC 
and the Krebs cycle, respectively96 (FIG. 4). ROS production 
is typically low under normal physiological conditions93, 
and is kept in check by intracellular and intramitochon-
drial scavenging systems. Pathological ROS levels in the 
heart typically occur when ROS production outpaces 
endogenous scavenging capacity. ROS (and other associ-
ated reactive intermediates) can damage proteins and 
lipids, trigger cell-death cascades, and evoke synchro-
nized collapses in the cellular energy grid97,98. Heightened 
mitochondrial ROS production and downstream ROS-
mediated damage has been reported in patients with HF 
as well as in preclinical models of the disease31,99–101.
Although ROS are typically associated with patho-
logical states, ROS levels in the heart per se are best 
characterized by the term ‘hormesis’: small amounts can 
evoke adaptive signalling and create beneficial, com-
pensatory responses. Modest production of ROS has 
been shown to mediate beneficial myocardial signalling 
involved in physiological responses such as (transient) 
sympathetic drive102, many preconditioning paradigms103, 
cardiac mitochondrial quality control104, and exercise105. 
Exercise training is known to augment endogenous ROS-
scavenging mechanisms in the heart105–107, restore bio-
energetic efficiency in porcine models of HFpEF108, and 
improve symptoms and quality of life in trials involving 
patients with HFrEF109,110 or HFpEF111. Consistent with 
the ROS hormesis concept, several studies have noted 
that administration of high doses of ROS scavengers can 
abolish the beneficial effects of exercise112,113, including 
humans taking oral vitamin C or E supplements114.
Mitochondrial production of ROS depends on the 
mitochondrial membrane potential. Increased expression 
of mitochondrial uncoupling proteins in HF115 might be a 
compensatory mechanism to reduce ROS by ‘uncoupling 
Figure 4 | Impaired mitochondrial energy production along the inner membrane. 
Enzyme complexes responsible for energy production are packed into the mitochondrial 
inner membrane, often with the help of phospholipids such as cardiolipin. Failing 
mitochondria often display altered morphology, decreased ATP-generating capacity, 
heightened production of reactive oxygen species (ROS), abnormal cardiolipin levels, 
and impaired supercomplexes.
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to survive’116, whereby a reduction in mitochondrial mem-
brane potential is postulated to lower ROS emission from 
mitochondria. This view is popular and almost dogmatic, 
but the decrease in ROS production by uncoupling is a 
prominent effect during mitochondrial state 4 respiration 
(no ADP). Heart mitochondria, however, are never respir-
ing in state 4. Pathological ROS production in cardio-
myocytes is likely to be more closely linked to decreased 
or collapsed membrane potential and/or depletion of 
the NADPH pool117–119, whereby ROS production over-
whelms endogenous scavenging through mitochondrial 
membrane-dependent mechanisms89.
The repeated lack of benefits of ROS scavenging 
compounds in clinical trials of patients with HF11,120,121 
continues to plague cardiovascular drug development, 
suggesting that oxygen radical scavenging per se is not a 
plausible mechanism of action for long-term improve-
ments in HF. Lack of tissue permeability, poor intra-
cellular targeting, and ineffective therapeutic doses 
might contribute to the poor translation of benefits of 
anti oxidants to date. This approach to therapy, however, 
might ultimately succeed when novel scavenging com-
pounds that overcome permeability and targeting prob-
lems, such as XJB-5-131 (REFS 122,123), mitoTEMPO124,125, 
and EUK8/EUK134 (REFS 126–128), are tested in humans.
Abnormalities of mitochondrial ETC
Decrements in individual electron transport complexes, 
particularly complex I and/or IV activity, have been 
observed in animal models129 and humans35 with HF. 
Electron transport system proteins seem to aggregate 
into functional supercomplexes130–132, and a loss of mito-
chondrial supercomplexes, which is postulated to have a 
causal role in mitochondrial ROS generation133, has been 
noted in HF134.
Several approaches are being developed to improve 
the efficiency of the ETC in HF. The coenzyme  Q 
(ubiquinol/ubiquinone CoQ) pool comprises a redox- 
cycling coenzyme found in the ETC. CoQ is typically 
synthesized de novo and undergoes a two-electron reduc-
tion from substrates fed into complexes I and II, and is 
then oxidized as it donates electrons into complex III. 
As a redox cycler, the ubiquinol/ubiquinone couple can 
both accept and donate electrons, depending on the redox 
potential135. Incomplete, one-electron reduction of CoQ 
produces semiquinone, itself a highly reactive radical. 
A reduced CoQ pool could potentially feed electrons 
‘backwards’ towards complex I, which results in reverse 
electron transfer and ROS generation136. Decreased cir-
culating CoQ has been observed in patients with HF137,138, 
with an inverse correlation observed between plasma 
CoQ and mortality139. In the Q-SYMBIO trial140, the effi-
cacy of CoQ was tested in a small (n = 420), double-blind, 
placebo- controlled study in patients with HF and showed a 
reduction in mortality after 2 years of treatment. Although 
the Q-SYMBIO trial was fairly small, the promising find-
ings triggered interest in the development of other CoQ 
analogues that more effectively target mitochondria. New 
quinone conjugates that are tethered to lipophilic, cationic 
triphenylphosphonium moieties, such as MitoQ, SkQ, and 
other plastoquinones, might improve the delivery of CoQ 
to mitochondria141–143, and have shown some promise in 
preclinical models of HF144. A potential problem with the 
use of these compounds is that they are self-limiting, in 
that they can depolarize mitochondria and inhibit mito-
chondrial respiration at high concentrations145. Several 
short-chain synthetic CoQ analogues are also in devel-
opment, including EPI-743 (REF. 146) and idebenone147. 
These compounds have shown promise in small trials of 
genetic mitochondrial disease148,149, but have not yet been 
tested in larger trials of human HF.
Aberrant mitochondrial membrane phospholipids in 
HF are integrally involved in ETC dysfunction. A mem-
brane phospholipid integral to optimal function of the 
ETC and whose content and composition are altered in 
HF is cardiolipin. Cardiolipin resides in the inner mito-
chondrial membrane (FIG. 4) and, unlike most phospho-
lipids that have two acyl tails, cardiolipin has four acyl 
chains. In mammalian hearts, these chains are enriched 
with linoleic acid (18:2)4. Cardiolipin decrements are 
observed in both paediatric150 and adult151,152 patients 
with HF. Cardiolipin is essential for the activity of ETC 
complexes, membrane transporters, mitochondrial ion 
homeostasis, and ROS production153. Given that most 
mitochondrial complexes associated with energy prod-
uction are oligomers composed of many subunits, cardio-
lipin is proposed to act as molecular ‘glue’ holding these 
subunits together154–156. Approaches that target cardiolipin 
are likely to improve electron transport across the ETC 
and, in doing so, might be beneficial in treating HF.
A compound that targets cardiolipin in the mito-
chondria that is currently in clinical development is the 
cell-permeable peptide MTP-131 (also called elamipretide 
or Bendavia). An analogue of MTP-131 (SS-31) was seren-
dipitously discovered by Szeto and Schiller in attempts 
to identify small peptides with opioid-receptor binding 
properties157. MTP-131 has no discernible opioid-receptor 
activity158, but was found to localize to the inner mito-
chondrial membrane159, reduce myocardial ischaemia–
reperfusion injury112,160,161, improve renal function51,162, 
and restore skeletal muscle function163. MTP-131 is not a 
direct ROS scavenger164, and is postulated to act by inter-
acting with cardiolipin165 to interrupt the vicious cycle of 
ROS-mediated cardiolipin oxidation and subsequent loss 
of energetics119,166. MTP-131-mediated improvements in 
mitochondrial energetics have been observed across a 
number of different tissues in animal models of disease, 
including the myocardium161,163,164. Of note, MTP-131 
can improve mitochondrial bioenergetics by improv-
ing respiratory supercomplex formation (D. A. Brown, 
 unpublished work).
MTP-131 is currently being investigated in several 
phase II clinical trials. Preclinical studies in mouse mod-
els of HF have demonstrated efficacy using MTP-131. 
In a mouse model of HF induced by aortic constriction, 
MTP-131 improved left ventricular function, reduced 
hypertrophic remodelling, and restored mitochon-
drial function167. In complementary studies, MTP-131 
administration substantially reduced mal adaptive 
remodelling, preserved cardiac function, lowered 
β-adrenergic- mediated calcium overload, and restored 
mitochondrial protein expression168–170. A substantial 
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improvement in cardiac function with MTP-131 has 
been demonstrated in a porcine model of HFpEF171 and 
a canine model of HFrEF172. Beneficial improvements in 
ejection fraction were associated with improved activity or 
expression of mitochondrial complexes I, IV, and V, and a 
normalization of cardiolipin levels172. As the HF syndrome 
influences many different tissues (FIG. 3), the evidence that 
MTP-131 also improves skeletal muscle function, exercise 
capacity, and renal function adds to the promise of this 
emerging therapy51,163,173,174.
Blockers of the MPTP
The mitochondrial permeability transition pore (MPTP) 
is a nonspecific pore that opens in response to increased 
calcium levels and oxidative challenge, and is associated 
with ROS production, apoptotic cell death, and mito-
chondrial dysfunction. Increased proclivity of MPTP 
opening occurs in both acute and chronic heart disease, 
and numerous preclinical studies have demonstrated effi-
cacy in cardiac pathology with MPTP blockers, such as 
cyclosporin, NIM811, and TRO40303 (reviewed previ-
ously175–179). Although the opening of the MPTP has his-
torically been thought of as a pathological event leading to 
cell death, studies now suggest that transient MPTP open-
ing might be a physiological ‘reset’ mechanism to prevent 
mitochondrial calcium overload. Rare, transient openings 
of the MPTP have been observed in individual mitochon-
dria of primary cardiomyocytes180. Small, brief MPTP 
openings were found to be more frequent in HF cardio-
myocytes, and were associated with transient mitochon-
drial depolarization and mitochondrial calcium release. 
If opening of these pores might be a normal compensatory 
mechanism akin to ‘pressure release valves’, the concept of 
treating HF by blocking them becomes increasingly diffi-
cult. Ongoing uncertainty regarding the molecular iden-
tity of the MPTP further complicates the development of 
novel therapies that act on the pore176,181–185. The MPTP 
seems to be comprised of ATP synthase (complex V) 
dimers and to be gated by mitochondrial matrix calcium 
content via cyclophillin D186,187.
Clinical studies have failed to demonstrate efficacy in 
most188,189, but not all190,191, studies; however, most of these 
studies focused on reducing acute cardiac ischaemia– 
reperfusion injury and not in limiting left ventricular dys-
function in HF. Chronic administration of cyclosporin has 
been linked with renal pathology and immunosuppres-
sion192,193, and cyclosporin was found to evoke systemic 
hypertension in porcine models of HFpEF194. Accordingly, 
cyclosporin is not an appropriate approach for the long-
term management of HF. Further work with alternative 
MPTP blockers is needed to determine whether inhibit-
ing or delaying MPTP opening is a  clinically plausible 
approach to alter the progression of HF.
Cellular/mitochondrial ion homeostasis
Aberrant handling of several different ions within the 
mitochondria has been observed, mostly in animal mod-
els of HF. Heightened levels of free iron can increase 
ROS through Fenton chemistry. Changes in cellular iron 
 handling have been noted in HF7,195, and orally-available 
iron chelators such as deferiprone seem to redistribute 
iron from tissues, including the mitochondrial space, 
into the circulation196. Although a potential exists to treat 
HF by chelating cellular iron, no study to date has shown 
functional improvements of the failing heart, although 
several clinical trials are currently underway.
Impaired cellular calcium handling that leads to 
decrements in excitation–contraction coupling is noted 
across HF aetiologies, and contributes to poor cardiac 
mechanics and to arrhythmogenesis197–200. Mitochondria 
can directly influence cellular calcium dynamics, because 
many of the membrane-bound pumps required for cyto-
solic calcium release and removal are energy- dependent 
and ROS-dependent. Altered calcium handling has 
been implicated in HFpEF, in which abnormal calcium 
dynamics impair relaxation. Short-term administration of 
ivabra dine to slow the heart rate led to modest benefits in 
patients with HFpEF, ostensibly by providing more time 
for calcium- dependent relaxation201. The vast majority 
of calcium resequestration into the sarcoplasmic reticu-
lum, obligatory for diastolic relaxation, occurs through 
SERCA2a, which has been shown to be downregulated 
in HF202–204. Overexpressing SERCA2a has shown prom-
ise in animal models of HF205,206, although several barri-
ers (such as the development of neutralizing antibodies) 
still exist before gene transfer realizes its full translational 
potential207. Furthermore, increased ROS can oxidize 
proteins associated with the ryanodine receptor calcium- 
release channel, which can lead to calcium leaking out of 
the sarcoplasmic reticulum during diastole208. Increased 
intracellular sodium levels in HF209–212 also contribute 
to poor calcium handling through mechanisms involv-
ing sodium–calcium exchange. Given that calcium is 
 central to maintaining bioenergetic supply–demand 
matching21,213, sodium overload alters cellular and mito-
chondrial calcium fluxes and impairs bioenergetic 
supply– demand matching in HF214. Although very early 
in development, inhibitors of the mitochondrial sodium–
calcium– (lithium) exchanger215, such as CGP-37157, have 
been shown to improve cardiac function in preclinical 
models of HF216,217. Inhibiting the sarcolemmal sodium– 
calcium exchanger might also be a promising approach, 
as  demonstrated in a preclinical model of HFpEF218.
Another compound in clinical development to 
improve cardiac efficiency in HF is omecamtiv mecarbil 
(CK-1827452). This drug increases the calcium sensitiv-
ity of the myofilaments219, which prolongs the duration 
of systole in animal models and in human HF220–222. Two 
substantial phase IIb, double-blind, randomized studies 
comparing omecamtiv mecarbil and placebo have been 
conducted. In the ATOMIC-HF trial223,  omecamtiv 
mecarbil was administered for 48 h intra venously to 
patients with acute HF. Overall, the study was  neutral 
(with some evidence of a symptomatic benefit at higher 
doses), but suggested omecamtiv mecarbil was safe. 
In the COSMIC-HF trial224, an oral formulation of 
omecam tiv mecarbil was associated with improvements 
in cardiac function over 20 weeks, with an effect that 
persisted for 4 weeks after stopping the drug, suggest-
ing that improved function had produced favourable 
structural remodelling. Despite the promise of omecam-
tiv mecarbil, concerns about elevated levels of serum 
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troponin225, metabolic inefficiency226, and impaired 
cardiac relaxation227 must be assuaged by larger clin-
ical trials to understand fully whether this approach can 
improve prognosis in HF.
Conclusions
The vast majority of HF trials over the past decade have 
been neutral, and event rates remain unacceptably high. 
Perhaps most alarming, no proven therapies exist for 
patients with worsening chronic HF or HFpEF — popu-
lations that collectively comprise the majority of the total 
HF population. Moreover, although systemic blockade 
of maladaptive neurohormonal responses has improved 
outcomes in HFrEF, these agents also lower blood 
pressure and/or heart rate, and development of new 
haemodynamically active drugs for stepwise addition to 
existing therapies raises safety and tolerability concerns. 
Therefore, an ideal novel therapy would be haemo-
dynamically neutral and target the myocardium as the 
centrepiece of the therapeutic mechanism. In this con-
text, overwhelming evidence from both preclinical and 
clinical studies indicates bioenergetic insufficiency in HF. 
Studies using preclinical models of the disease continue 
to advance our understanding of the cellular and molecu-
lar mechanisms that contribute to poor bio energetics 
of the failing heart. Considerable potential exists to fill 
this unmet need, mitigate the economic burdens, and 
reduce symptoms in patients with HF by focusing on the 
development of new therapeutic  modalities that target 
 mitochondrial abnormalities in HF.
1. Jessup, M. et al. 2009 focused update: ACCF/AHA 
guidelines for the diagnosis and management of heart 
failure in adults: a report of the American College of 
Cardiology Foundation/American Heart Association 
Task Force on Practice Guidelines: developed in 
collaboration with the International Society for 
Heart and Lung Transplantation. Circulation 119,  
1977–2016 (2009).
2. Hunt, S. A. et al. ACC/AHA 2005 guideline update for 
the diagnosis and management of chronic heart failure 
in the adult: a report of the American College of 
Cardiology/American Heart Association Task Force on 
Practice Guidelines (Writing Committee to Update the 
2001 Guidelines for the Evaluation and Management 
of Heart Failure): developed in collaboration with 
the American College of Chest Physicians and 
the International Society for Heart and Lung 
Transplantation: endorsed by the Heart Rhythm 
Society. Circulation 112, e154–e235 (2005).
3. Wilcox, J. E. et al. “Targeting the Heart” in heart 
failure: myocardial recovery in heart failure with 
reduced ejection fraction. JACC Heart Fail. 3,  
661–669 (2015).
4. Braunschweig, F., Cowie, M. R. & Auricchio, A. What 
are the costs of heart failure? Europace 13, ii13–ii17 
(2011).
5. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the 
management of heart failure: a report of the American 
College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. J. Am. 
Coll. Cardiol. 62, e147–e239 (2013).
6. Meta-analysis Global Group in Chronic Heart Failure. 
The survival of patients with heart failure with 
preserved or reduced left ventricular ejection fraction: 
an individual patient data meta-analysis. Eur. Heart J. 
33, 1750–1757 (2012).
7. Bayeva, M., Gheorghiade, M. & Ardehali, H. 
Mitochondria as a therapeutic target in heart failure. 
J. Am. Coll. Cardiol. 61, 599–610 (2013).
8. Neely, J. R., Liebermeister, H., Battersby, E. J. 
& Morgan, H. E. Effect of pressure development 
on oxygen consumption by isolated rat heart. 
Am. J. Physiol. 212, 804–814 (1967).
9. Gheorghiade, M. et al. Developing new treatments 
for heart failure: focus on the heart. Circ. Heart Fail.  
9, e002727 (2016).
10. Vaduganathan, M., Butler, J., Pitt, B. 
& Gheorghiade, M. Contemporary drug development 
in heart failure: call for hemodynamically neutral 
therapies. Circ. Heart Fail. 8, 826–831 (2015).
11. Downey, J. M. & Cohen, M. V. Why do we still not have 
cardioprotective drugs? Circ. J. 73, 1171–1177 
(2009).
12. Senni, M., Gavazzi, A., Gheorghiade, M. & Butler, J. 
Heart failure at the crossroads: moving beyond 
blaming stakeholders to targeting the heart. 
Eur. J. Heart Fail. 17, 760–763 (2015).
13. Fordyce, C. B. et al. Cardiovascular drug development: 
is it dead or just hibernating? J. Am. Coll. Cardiol. 65, 
1567–1582 (2015).
14. Amidon, S. & Amidon, T. The Sublime Engine: A 
Biography of the Human Heart. (Rodale Books, 2011).
15. Tornroth-Horsefield, S. & Neutze, R. Opening and 
closing the metabolite gate. Proc. Natl Acad. Sci. USA 
105, 19565–19566 (2008).
16. Balaban, R. S. Cardiac energy metabolism 
homeostasis: role of cytosolic calcium. J. Mol. Cell. 
Cardiol. 34, 1259–1271 (2002).
17. Barth, E., Stammler, G., Speiser, B. & Schaper, J. 
Ultrastructural quantitation of mitochondria and 
myofilaments in cardiac muscle from 10 different 
animal species including man. J. Mol. Cell. Cardiol. 24, 
669–681 (1992).
18. Schaper, J., Meiser, E. & Stammler, G. Ultrastructural 
morphometric analysis of myocardium from dogs, rats, 
hamsters, mice, and from human hearts. Circ. Res. 56, 
377–391 (1985).
19. Opie, L. The Heart: Physiology, from Cell to Circulation 
3rd edn, (Lipincott−Raven, 1998).
20. Balaban, R. S. Domestication of the cardiac 
mitochondrion for energy conversion. J. Mol. Cell. 
Cardiol. 6, 832–841 (2009).
21. Balaban, R. S. The role of Ca2+ signaling in the 
coordination of mitochondrial ATP production 
with cardiac work. Biochim. Biophys. Acta 1787,  
1334–1341 (2009).
22. Suliman, H. B. & Piantadosi, C. A. Mitochondrial quality 
control as a therapeutic target. Pharmacol. Rev. 68, 
20–48 (2016).
23. Lesnefsky, E. J., Chen, Q. & Hoppel, C. L. Mitochondrial 
metabolism in aging heart. Circ. Res. 118, 1593–1611 
(2016).
24. Gottlieb, R. A. & Bernstein, D. Mitochondrial 
remodeling: rearranging, recycling, and 
reprogramming. Cell Calcium 60, 88–101 (2016).
25. Shirihai, O. S., Song, M. & Dorn, G. W. II. How 
mitochondrial dynamism orchestrates mitophagy. 
Circ. Res. 116, 1835–1849 (2015).
26. Dorn, G. W., II & Kitsis, R. N. The mitochondrial 
dynamism-mitophagy-cell death interactome: multiple 
roles performed by members of a mitochondrial 
molecular ensemble. Circ. Res. 116, 167–182 (2015).
27. Biala, A. K., Dhingra, R. & Kirshenbaum, L. A. 
Mitochondrial dynamics: orchestrating the journey to 
advanced age. J. Mol. Cell. Cardiol. 83, 37–43 (2015).
28. Dhingra, R. & Kirshenbaum, L. A. Regulation of 
mitochondrial dynamics and cell fate. Circ. J. 78,  
803–810 (2014).
29. Thomas, R. L. & Gustafsson, A. B. Mitochondrial 
autophagy — an essential quality control mechanism 
for myocardial homeostasis. Circ. J. 77, 2449–2454 
(2013).
30. Sebastiani, M. et al. Induction of mitochondrial 
biogenesis is a maladaptive mechanism in 
mitochondrial cardiomyopathies. J. Am. Coll. Cardiol. 
50, 1362–1369 (2007).
31. Goh, K. Y. et al. Impaired mitochondrial network 
excitability in failing guinea-pig cardiomyocytes. 
Cardiovasc. Res. 109, 79–89 (2016).
32. Sabbah, H. N. et al. Mitochondrial abnormalities in 
myocardium of dogs with chronic heart failure. J. Mol. 
Cell. Cardiol. 24, 1333–1347 (1992).
33. Lehman, J. J. & Kelly, D. P. Gene regulatory 
mechanisms governing energy metabolism during 
cardiac hypertrophic growth. Heart Fail. Rev. 7,  
175–185 (2002).
34. Lai, L. et al. Energy metabolic reprogramming in 
the hypertrophied and early stage failing heart: 
a multisystems approach. Circ. Heart Fail. 7,  
1022–1031 (2014).
35. Lemieux, H., Semsroth, S., Antretter, H., Hofer, D. 
& Gnaiger, E. Mitochondrial respiratory control and 
early defects of oxidative phosphorylation in the 
failing human heart. Int. J. Biochem. Cell Biol. 43,  
1729–1738 (2011).
36. Nicholls, D. G. & Ferguson, S. J. Bioenergetics 3rd edn 
(Academic, 2002).
37. Schon, E. A., DiMauro, S. & Hirano, M. Human 
mitochondrial DNA: roles of inherited and somatic 
mutations. Nat. Rev. Genet. 13, 878–890 (2012).
38. Ott, M., Amunts, A. & Brown, A. Organization 
and regulation of mitochondrial protein synthesis. 
Annu. Rev. Biochem. 85, 77–101 (2016).
39. Bates, M. G. et al. Cardiac involvement in 
mitochondrial DNA disease: clinical spectrum, 
diagnosis, and management. Eur. Heart J. 33,  
3023–3033 (2012).
40. Margulis, L. Symbiotic theory of the origin of eukaryotic 
organelles; criteria for proof. Symp. Soc. Exp. Biol. 29 
21–38 (1975).
41. Sato, M. & Sato, K. Maternal inheritance of 
mitochondrial DNA by diverse mechanisms to eliminate 
paternal mitochondrial DNA. Biochim. Biophys. Acta 
1833, 1979–1984 (2013).
42. Taylor, R. W. & Turnbull, D. M. Mitochondrial DNA 
mutations in human disease. Nat. Rev. Genet. 6,  
389–402 (2005).
43. Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S. 
& Moraes, C. T. Specific elimination of mutant 
mitochondrial genomes in patient-derived cells 
by mitoTALENs. Nat. Med. 19, 1111–1113 (2013).
44. Reddy, P. et al. Selective elimination of mitochondrial 
mutations in the germline by genome editing. Cell 161, 
459–469 (2015).
45. Paull, D. et al. Nuclear genome transfer in human 
oocytes eliminates mitochondrial DNA variants. Nature 
493, 632–637 (2013).
46. Mitchell, P. Coupling of phosphorylation to electron 
and hydrogen transfer by a chemi-osmotic type of 
mechanism. Nature 191, 144–148 (1961).
47. Carrasco, A. J. et al. Adenylate kinase phosphotransfer 
communicates cellular energetic signals to ATP-
sensitive potassium channels. Proc. Natl Acad. Sci. USA 
98, 7623–7628 (2001).
48. Wu, F., Zhang, J. & Beard, D. A. Experimentally 
observed phenomena on cardiac energetics in 
heart failure emerge from simulations of cardiac 
metabolism. Proc. Natl Acad. Sci. USA 106,  
7143–7148 (2009).
49. Neubauer, S. et al. Downregulation of the Na+-creatine 
cotransporter in failing human myocardium and 
in experimental heart failure. Circulation 100,  
1847–1850 (1999).
50. Abozguia, K. et al. Reduced in vivo skeletal muscle 
oxygen consumption in patients with chronic heart 
failure — a study using Near Infrared 
Spectrophotometry (NIRS). Eur. J. Heart Fail. 10,  
652–657 (2008).
51. Eirin, A. et al. Mitochondrial protection restores renal 
function in swine atherosclerotic renovascular disease. 
Cardiovasc. Res. 103, 461–472 (2014).
52. Anderson, E. J. et al. Mitochondrial H2O2 emission 
and cellular redox state link excess fat intake to insulin 
resistance in both rodents and humans. J. Clin. Invest. 
3, 573–581 (2009).
C O N S E N S U S  S TAT E M E N T
10 | ADVANCE ONLINE PUBLICATION www.nature.com/nrcardio
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
53. Zhang, Q. et al. Catechin ameliorates cardiac 
dysfunction in rats with chronic heart failure by 
regulating the balance between Th17 and Treg cells. 
Inflamm. Res. 63, 619–628 (2014).
54. Ramirez-Sanchez, I. et al. (−)-Epicatechin rich cocoa 
mediated modulation of oxidative stress regulators 
in skeletal muscle of heart failure and type 2 diabetes 
patients. Int. J. Cardiol. 168, 3982–3990 (2013).
55. Sung, M. M. & Dyck, J. R. Therapeutic potential of 
resveratrol in heart failure. Ann. NY Acad. Sci. 1348, 
32–45 (2015).
56. Magyar, K. et al. Cardioprotection by resveratrol: 
a human clinical trial in patients with stable coronary 
artery disease. Clin. Hemorheol. Microcirc. 50,  
179–187 (2012).
57. Stanley, W. C., Recchia, F. A. & Lopaschuk, G. D. 
Myocardial substrate metabolism in the normal and 
failing heart. Physiol. Rev. 85, 1093–1129 (2005).
58. Doenst, T., Nguyen, T. D. & Abel, E. D. Cardiac 
metabolism in heart failure: implications beyond ATP 
production. Circ. Res. 113, 709–724 (2013).
59. Fukushima, A., Milner, K., Gupta, A. & Lopaschuk, G. D. 
Myocardial energy substrate metabolism in heart 
failure: from pathways to therapeutic targets. 
Curr. Pharm. Des. 21, 3654–3664 (2015).
60. Ventura-Clapier, R., Garnier, A. & Veksler, V. Energy 
metabolism in heart failure. J. Physiol. 555, 1–13 
(2004).
61. Aubert, G., Vega, R. B. & Kelly, D. P. Perturbations 
in the gene regulatory pathways controlling 
mitochondrial energy production in the failing heart. 
Biochim. Biophys. Acta 1833, 840–847 (2013).
62. de las Fuentes, L. et al. Myocardial fatty acid 
metabolism: independent predictor of left ventricular 
mass in hypertensive heart disease. Hypertension 41, 
83–87 (2003).
63. Goikoetxea, M. J. et al. Altered cardiac expression 
of peroxisome proliferator-activated receptor-
isoforms in patients with hypertensive heart disease. 
Cardiovasc. Res. 69, 899–907 (2006).
64. Sack, M. N. et al. Fatty acid oxidation enzyme gene 
expression is downregulated in the failing heart. 
Circulation 94, 2837–2842 (1996).
65. Sihag, S., Cresci, S., Li, A. Y., Sucharov, C. C. 
& Lehman, J. J. PGC‑1α and ERRα target gene 
downregulation is a signature of the failing human 
heart. J. Mol. Cell. Cardiol. 46, 201–212 (2009).
66. Lehman, J. J. et al. Peroxisome proliferator-activated 
receptor γ coactivator-1 promotes cardiac 
mitochondrial biogenesis. J. Clin. Invest. 106,  
847–856 (2000).
67. Sarma, S., Ardehali, H. & Gheorghiade, M. Enhancing 
the metabolic substrate: PPAR-alpha agonists in heart 
failure. Heart Fail. Rev. 17, 35–43 (2012).
68. Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R. 
& Lopaschuk, G. D. Targeting fatty acid and 
carbohydrate oxidation — a novel therapeutic 
intervention in the ischemic and failing heart. 
Biochim. Biophys. Acta 1813, 1333–1350 (2011).
69. Igarashi, N. et al. Influence of β-adrenoceptor blockade 
on the myocardial accumulation of fatty acid tracer and 
its intracellular metabolism in the heart after ischemia−
reperfusion injury. Circ. J. 70, 1509–1514 (2006).
70. Fillmore, N. & Lopaschuk, G. D. Malonyl CoA: 
a promising target for the treatment of cardiac disease. 
IUBMB Life http://dx.doi.org/10.1002/iub.1253 
(2014).
71. Stanley, W. C. et al. Malonyl-CoA decarboxylase 
inhibition suppresses fatty acid oxidation and reduces 
lactate production during demand-induced ischemia. 
Am. J. Physiol. Heart Circ. Physiol. 289,  
H2304–H2309 (2005).
72. Dyck, J. R. et al. Malonyl coenzyme A decarboxylase 
inhibition protects the ischemic heart by inhibiting fatty 
acid oxidation and stimulating glucose oxidation. 
Circ. Res. 94, e78–e84 (2004).
73. Kolwicz, S. C. Jr., Airhart, S. & Tian, R. Ketones step 
to the plate: a game changer for metabolic remodeling 
in heart failure? Circulation 133, 689–691 (2016).
74. Bedi, K. C. Jr. et al. Evidence for intramyocardial 
disruption of lipid metabolism and increased 
myocardial ketone utilization in advanced human heart 
failure. Circulation 133, 706–716 (2016).
75. Pinti, M. V., Hathaway, Q. A. & Hollander, J. M. 
Role of microRNA in metabolic shift during heart failure. 
Am. J. Physiol. Heart Circ. Physiol. http://dx.doi.org/ 
10.1152/ajpheart.00341.2016 (2016).
76. Opie, L. H., Thandroyen, F. T., Muller, C. 
& Bricknell, O. L. Adrenaline-induced “oxygen-wastage” 
and enzyme release from working rat heart. Effects 
of calcium antagonism, β-blockade, nicotinic acid 
and coronary artery ligation. J. Mol. Cell. Cardiol. 11, 
1073–1094 (1979).
77. Francis, G. S. et al. Plasma norepinephrine, plasma 
renin activity, and congestive heart failure. Relations 
to survival and the effects of therapy in V-HeFT II. 
The V-HeFT VA Cooperative Studies Group. Circulation 
87, VI40–V148 (1993).
78. Triposkiadis, F. et al. The sympathetic nervous system 
in heart failure physiology, pathophysiology, and clinical 
implications. J. Am. Coll. Cardiol. 54, 1747–1762 
(2009).
79. Menon, B. et al. Expression of the cytoplasmic domain 
of β1 integrin induces apoptosis in adult rat ventricular 
myocytes (ARVM) via the involvement of caspase-8 and 
mitochondrial death pathway. Basic Res. Cardiol. 101, 
485–493 (2006).
80. Rosca, M. G. & Hoppel, C. L. Mitochondrial dysfunction 
in heart failure. Heart Fail. Rev. 18, 607–622 (2013).
81. Leger, B. et al. Chronic formoterol administration 
reduces cardiac mitochondrial protein synthesis 
and oxidative capacity in mice. Int. J. Cardiol. 146, 
270–272 (2011).
82. Izem-Meziane, M. et al. Catecholamine-induced cardiac 
mitochondrial dysfunction and mPTP opening: 
protective effect of curcumin. Am. J. Physiol. Heart Circ. 
Physiol. 302, H665–674 (2012).
83. Nagasaka, S. et al. Protein kinase A catalytic subunit 
alters cardiac mitochondrial redox state and membrane 
potential via the formation of reactive oxygen species. 
Circ. J. 71, 429–436 (2007).
84. Remondino, A. et al. β-adrenergic receptor-stimulated 
apoptosis in cardiac myocytes is mediated by reactive 
oxygen species/c-Jun NH2-terminal kinase-dependent 
activation of the mitochondrial pathway. Circ. Res. 92, 
136–138 (2003).
85. Communal, C., Colucci, W. S. & Singh, K. p38 mitogen-
activated protein kinase pathway protects adult rat 
ventricular myocytes against β -adrenergic receptor-
stimulated apoptosis. Evidence for Gi-dependent 
activation. J. Biol. Chem. 275, 19395–19400 (2000).
86. Communal, C., Singh, K., Sawyer, D. B. & Colucci, W. S. 
Opposing effects of β1- and β2-adrenergic receptors 
on cardiac myocyte apoptosis: role of a pertussis 
toxin-sensitive G protein. Circulation 100, 2210–2212 
(1999).
87. Liaudet, L., Calderari, B. & Pacher, P. Pathophysiological 
mechanisms of catecholamine and cocaine-mediated 
cardiotoxicity. Heart Fail. Rev. 19, 815–824 (2014).
88. Feldman, D. S., Carnes, C. A., Abraham, W. T. 
& Bristow, M. R. Mechanisms of disease: β-adrenergic 
receptors — alterations in signal transduction and 
pharmacogenomics in heart failure. Nat. Clin. Pract. 
Cardiovasc. Med. 2, 475–483 (2005).
89. Aon, M. A., Cortassa, S. & O’Rourke, B. Redox-
optimized ROS balance: a unifying hypothesis. 
Biochim. Biophys. Acta 6, 865–877 (2010).
90. Brown, D. A., Sabbah, H. N. & Shaikh, S. R. 
Mitochondrial inner membrane lipids and proteins 
as targets for decreasing cardiac ischemia/reperfusion 
injury. Pharmacol. Ther. 140, 258–266 (2013).
91. Murphy, E. & Steenbergen, C. Mechanisms underlying 
acute protection from cardiac ischemia−reperfusion 
injury. Physiol. Rev. 88, 581–609 (2008).
92. Murphy, E. & Steenbergen, C. Ion transport and 
energetics during cell death and protection. Physiology 
(Bethesda) 23, 115–123 (2008).
93. Murphy, M. P. How mitochondria produce reactive 
oxygen species. Biochem. J. 417, 1–13 (2009).
94. Walters, A. M., Porter, G. A. Jr & Brookes, P. S. 
Mitochondria as a drug target in ischemic heart disease 
and cardiomyopathy. Circ. Res. 111, 1222–1236 
(2012).
95. Nabeebaccus, A., Zhang, M. & Shah, A. M. NADPH 
oxidases and cardiac remodelling. Heart Fail. Rev. 16, 
5–12 (2011).
96. Orr, A. L. et al. Inhibitors of ROS production by the 
ubiquinone-binding site of mitochondrial complex I 
identified by chemical screening. Free Radic. Biol. Med. 
65, 1047–1059 (2013).
97. Zorov, D. B., Juhaszova, M. & Sollott, S. J. 
Mitochondrial ROS-induced ROS release: an update 
and review. Biochim. Biophys. Acta 1757, 509–517 
(2006).
98. Aon, M. A., Cortassa, S., Akar, F. G. & O’Rourke, B. 
Mitochondrial criticality: a new concept at the turning 
point of life or death. Biochim. Biophys. Acta 1762, 
232–240 (2006).
99. Ide, T. et al. Mitochondrial DNA damage and 
dysfunction associated with oxidative stress in failing 
hearts after myocardial infarction. Circ. Res. 88,  
529–535 (2001).
100. Ide, T. et al. Direct evidence for increased hydroxyl 
radicals originating from superoxide in the failing 
myocardium. Circ. Res. 86, 152–157 (2000).
101. Ide, T. et al. Mitochondrial electron transport complex I 
is a potential source of oxygen free radicals in the 
failing myocardium. Circ. Res. 85, 357–363 (1999).
102. Rosca, M. G., Tandler, B. & Hoppel, C. L. Mitochondria 
in cardiac hypertrophy and heart failure. J. Mol. Cell. 
Cardiol. 55, 31–41 (2013).
103. Alleman, R. J., Katunga, L. A., Nelson, M. A., 
Brown, D. A. & Anderson, E. J. The “Goldilocks Zone” 
from a redox perspective — adaptive versus 
deleterious responses to oxidative stress in striated 
muscle. Front. Physiol. 5, 358 (2014).
104. Song, M. et al. Super-suppression of mitochondrial 
reactive oxygen species signaling impairs 
compensatory autophagy in primary mitophagic 
cardiomyopathy. Circ. Res. 115, 348–353 (2014).
105. Frasier, C. R., Moore, R. L. & Brown, D. A. 
Exercise-induced cardiac preconditioning: how exercise 
protects your achy-breaky heart. J. Appl. Physiol. 111, 
905–915 (2011).
106. Brown, D. A., Jew, K. N., Sparagna, G. C., Musch, T. I. 
& Moore, R. L. Exercise training preserves coronary 
flow and reduces infarct size following ischemia−
reperfusion in rat heart. J. Appl. Physiol. 95,  
2510–2518 (2003).
107. Brown, D. A. & Moore, R. L. Perspectives in innate and 
acquired cardioprotection: cardioprotection acquired 
through exercise. J. Appl. Physiol. 103, 1894–1899 
(2007).
108. Marshall, K. D. et al. Heart failure with preserved 
ejection fraction: chronic low-intensity interval exercise 
training preserves myocardial O2 balance and diastolic 
function. J. Appl. Physiol. 114, 131–147 (2013).
109. Flynn, K. E. et al. Effects of exercise training on health 
status in patients with chronic heart failure: 
HF-ACTION randomized controlled trial. JAMA 301, 
1451–1459 (2009).
110. O’Connor, C. M. et al. Efficacy and safety of exercise 
training in patients with chronic heart failure: 
HF-ACTION randomized controlled trial. JAMA 301, 
1439–1450 (2009).
111. Edelmann, F. et al. Exercise training improves exercise 
capacity and diastolic function in patients with heart 
failure with preserved ejection fraction: results of the 
Ex-DHF (Exercise training in Diastolic Heart Failure) 
pilot study. J. Am. Coll. Cardiol. 58, 1780–1791 
(2011).
112. Frasier, C. R. et al. Redox-dependent increases in 
glutathione reductase and exercise preconditioning: 
role of NADPH oxidase and mitochondria. 
Cardiovasc. Res. 98, 47–55 (2013).
113. Nelson, M. J., Harris, M. B., Boluyt, M. O., 
Hwang, H. S. & Starnes, J. W. Effect of 
N-2-mercaptopropionyl glycine on exercise-induced 
cardiac adaptations. Am. J. Physiol. Regul. Integr. 
Comp. Physiol. 300, R993–R1000 (2011).
114. Ristow, M. et al. Antioxidants prevent health-
promoting effects of physical exercise in humans. 
Proc. Natl Acad. Sci. USA 106, 8665–8670 (2009).
115. Akhmedov, A. T., Rybin, V. & Marin-Garcia, J. 
Mitochondrial oxidative metabolism and uncoupling 
proteins in the failing heart. Heart Fail. Rev. 20,  
227–249 (2015).
116. Brand, M. D. Uncoupling to survive? The role of 
mitochondrial inefficiency in ageing. Exp. Gerontol. 35, 
811–820 (2000).
117. Slodzinski, M. K., Aon, M. A. & O’Rourke, B. 
Glutathione oxidation as a trigger of mitochondrial 
depolarization and oscillation in intact hearts. J. Mol. 
Cell. Cardiol. 45, 650–660 (2008).
118. Brown, D. A. et al. Cardiac arrhythmias induced by 
glutathione oxidation can be inhibited by preventing 
mitochondrial depolarization. J. Mol. Cell. Cardiol. 48, 
673–679 (2010).
119. Nickel, A. G. et al. Reversal of mitochondrial 
transhydrogenase causes oxidative stress in heart 
failure. Cell Metab. 22, 472–484 (2015).
120. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J. 
& Sleight, P. Vitamin E supplementation and 
cardiovascular events in high-risk patients. Heart 
Outcomes Prevention Evaluation Study Investigators. 
N. Engl. J. Med. 342, 154–160 (2000).
121. Tsujita, K. et al. Effects of edaravone on reperfusion 
injury in patients with acute myocardial infarction. 
Am. J. Cardiol. 94, 481–484 (2004).
122. Escobales, N. et al. Mitochondria-targeted ROS 
scavenger improves post-ischemic recovery of cardiac 
function and attenuates mitochondrial abnormalities 
in aged rats. J. Mol. Cell. Cardiol. 77, 136–146 (2014).
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | CARDIOLOGY  ADVANCE ONLINE PUBLICATION | 11
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
123. Javadov, S. et al. Mitochondria-targeted antioxidant 
preserves contractile properties and mitochondrial 
function of skeletal muscle in aged rats. Oncotarget 6, 
39469–39481 (2015).
124. Dikalova, A. E. et al. Therapeutic targeting of 
mitochondrial superoxide in hypertension. Circ. Res. 
107, 106–116 (2010).
125. Liang, H. L., Sedlic, F., Bosnjak, Z. & Nilakantan, V. 
SOD1 and MitoTEMPO partially prevent 
mitochondrial permeability transition pore opening, 
necrosis, and mitochondrial apoptosis after ATP 
depletion recovery. Free Radic. Biol. Med. 49,  
1550–1560 (2010).
126. Koyama, H. et al. Antioxidants improve the 
phenotypes of dilated cardiomyopathy and muscle 
fatigue in mitochondrial superoxide dismutase-
deficient mice. Molecules 18, 1383–1393 (2013).
127. Kawakami, S. et al. Antioxidant, EUK-8, prevents 
murine dilated cardiomyopathy. Circ. J. 73,  
2125–2134 (2009).
128. van Empel, V. P. et al. EUK-8, a superoxide dismutase 
and catalase mimetic, reduces cardiac oxidative stress 
and ameliorates pressure overload-induced heart 
failure in the harlequin mouse mutant. J. Am. Coll. 
Cardiol. 48, 824–832 (2006).
129. Rosca, M., Minkler, P. & Hoppel, C. L. Cardiac 
mitochondria in heart failure: normal cardiolipin 
profile and increased threonine phosphorylation 
of complex IV. Biochim. Biophys. Acta 1807,  
1373–1382 (2011).
130. Acin-Perez, R. et al. Respiratory complex III is required 
to maintain complex I in mammalian mitochondria. 
Mol. Cell 13, 805–815 (2004).
131. Acin-Perez, R., Fernandez-Silva, P., Peleato, M. L., 
Perez-Martos, A. & Enriquez, J. A. Respiratory active 
mitochondrial supercomplexes. Mol. Cell 32,  
529–539 (2008).
132. Lapuente-Brun, E. et al. Supercomplex assembly 
determines electron flux in the mitochondrial electron 
transport chain. Science 340, 1567–1570 (2013).
133. Maranzana, E., Barbero, G., Falasca, A. I., Lenaz, G. 
& Genova, M. L. Mitochondrial respiratory 
supercomplex association limits production of reactive 
oxygen species from complex I. Antioxid. Redox 
Signal. 19, 1469–1480 (2013).
134. Rosca, M. G. et al. Cardiac mitochondria in heart 
failure: decrease in respirasomes and oxidative 
phosphorylation. Cardiovasc. Res. 80, 30–39 (2008).
135. Nicholls, D. G. & Ferguson, S. J. Bioenergetics 4th edn 
(Academic, 2013).
136. Chouchani, E. T. et al. Ischaemic accumulation 
of succinate controls reperfusion injury through 
mitochondrial ROS. Nature 515, 431–435 (2014).
137. Okonko, D. O. & Shah, A. M. Heart failure: 
mitochondrial dysfunction and oxidative stress in CHF. 
Nat. Rev. Cardiol. 12, 6–8 (2015).
138. Molyneux, S. L. et al. Coenzyme Q10: an independent 
predictor of mortality in chronic heart failure. J. Am. 
Coll. Cardiol. 52, 1435–1441 (2008).
139. McMurray, J. J. et al. Coenzyme Q10, rosuvastatin, 
and clinical outcomes in heart failure: a pre-specified 
substudy of CORONA (controlled rosuvastatin 
multinational study in heart failure). J. Am. Coll. 
Cardiol. 56, 1196–1204 (2010).
140. Mortensen, S. A. et al. The effect of coenzyme Q10 
on morbidity and mortality in chronic heart failure: 
results from Q-SYMBIO: a randomized double-blind 
trial. JACC Heart Fail. 2, 641–649 (2014).
141. Murphy, M. P. Targeting lipophilic cations to 
mitochondria. Biochim. Biophys. Acta 1777,  
1028–1031 (2008).
142. Smith, R. A. et al. Mitochondria-targeted antioxidants 
in the treatment of disease. Ann. NY Acad. Sci. 1147, 
105–111 (2008).
143. Skulachev, V. P. et al. An attempt to prevent 
senescence: a mitochondrial approach. 
Biochim. Biophys. Acta 1787, 437–461 (2009).
144. Graham, D. et al. Mitochondria-targeted antioxidant 
MitoQ10 improves endothelial function and attenuates 
cardiac hypertrophy. Hypertension 54, 322–328 
(2009).
145. Lyamzaev, K. G. et al. Novel mitochondria-targeted 
antioxidants: plastoquinone conjugated with cationic 
plant alkaloids berberine and palmatine. Pharm. Res. 
28, 2883–2895 (2011).
146. Enns, G. M. Treatment of mitochondrial disorders: 
antioxidants and beyond. J. Child Neurol. 29,  
1235–1240 (2014).
147. Jaber, S. & Polster, B. M. Idebenone and 
neuroprotection: antioxidant, pro-oxidant, or electron 
carrier? J. Bioenerg. Biomembr. 47, 111–118 (2015).
148. Sadun, A. A. et al. Effect of EPI-743 on the clinical 
course of the mitochondrial disease Leber hereditary 
optic neuropathy. Arch. Neurol. 69, 331–338 (2012).
149. Lerman-Sagie, T. et al. Dramatic improvement in 
mitochondrial cardiomyopathy following treatment with 
idebenone. J. Inherit Metab. Dis. 24, 28–34 (2001).
150. Chatfield, K. C. et al. Dysregulation of cardiolipin 
biosynthesis in pediatric heart failure. J. Mol. Cell. 
Cardiol. 74, 251–259 (2014).
151. Saini-Chohan, H. K. et al. Cardiolipin biosynthesis and 
remodeling enzymes are altered during development 
of heart failure. J. Lipid Res. 50, 1600–1608 (2009).
152. Sparagna, G. C. & Lesnefsky, E. J. Cardiolipin 
remodeling in the heart. J. Cardiovasc. Pharmacol. 53, 
290–301 (2009).
153. Chicco, A. J. & Sparagna, G. C. Role of cardiolipin 
alterations in mitochondrial dysfunction and disease. 
Am. J. Physiol. Cell Physiol. 292, C33–C44 (2007).
154. Pfeiffer, K. et al. Cardiolipin stabilizes respiratory chain 
supercomplexes. J. Biol. Chem. 278, 52873–52880 
(2003).
155. Schagger, H. Respiratory chain supercomplexes of 
mitochondria and bacteria. Biochim. Biophys. Acta 
1555, 154–159 (2002).
156. Zhang, M., Mileykovskaya, E. & Dowhan, W. Gluing the 
respiratory chain together. Cardiolipin is required for 
supercomplex formation in the inner mitochondrial 
membrane. J. Biol. Chem. 277, 43553–43556 (2002).
157. Szeto, H. H. & Birk, A. V. Serendipity and the discovery 
of novel compounds that restore mitochondrial 
plasticity. Clin. Pharmacol. Ther. 96, 672–683 (2014).
158. Szeto, H. H. & Schiller, P. W. Novel therapies targeting 
inner mitochondrial membrane — from discovery to 
clinical development. Pharm. Res. 28, 2669–2671 
(2011).
159. Szeto, H. H. Mitochondria-targeted cytoprotective 
peptides for ischemia−reperfusion injury. 
Antioxid. Redox Signal. 10, 601–619 (2008).
160. Sloan, R. C. et al. Mitochondrial permeability transition 
in the diabetic heart: contributions of thiol redox state 
and mitochondrial calcium to augmented reperfusion 
injury. J. Mol. Cell. Cardiol. 52, 1009–1018 (2012).
161. Kloner, R. A. et al. Reduction of ischemia/reperfusion 
injury with bendavia, a mitochondria-targeting 
cytoprotective peptide. J. Am. Heart Assoc. 1, 
e001644 (2012).
162. Szeto, H. H. et al. Mitochondria-targeted peptide 
accelerates ATP recovery and reduces ischemic kidney 
injury. J. Am. Soc. Nephrol. 22, 1041–1052 (2011).
163. Siegel, M. P. et al. Mitochondrial-targeted peptide 
rapidly improves mitochondrial energetics and skeletal 
muscle performance in aged mice. Aging Cell 12,  
763–771 (2013).
164. Brown, D. A. et al. Reduction of early reperfusion injury 
with the mitochondria-targeting peptide bendavia. 
J. Cardiovasc. Pharmacol. Ther.19, 121–132 (2013).
165. Birk, A. V., Chao, W. M., Bracken, C., Warren, J. D. 
& Szeto, H. H. Targeting mitochondrial cardiolipin 
and the cytochrome c/cardiolipin complex to promote 
electron transport and optimize mitochondrial ATP 
synthesis. Br. J. Pharmacol. 171, 2017–2028 (2013).
166. Birk, A. V. et al. The mitochondrial-targeted compound 
SS-31 re-energizes ischemic mitochondria by 
interacting with cardiolipin. J. Am. Soc. Nephrol. 24, 
1250–1261 (2013).
167. Dai, D. F. et al. Mitochondrial targeted antioxidant 
peptide ameliorates hypertensive cardiomyopathy. 
J. Am. Coll. Cardiol. 58, 73–82 (2011).
168. Dai, D. F. et al. Global proteomics and pathway analysis 
of pressure-overload-induced heart failure and its 
attenuation by mitochondrial-targeted peptides. 
Circ. Heart Fail. 6, 1067–1076 (2013).
169. Shi, J. et al. Bendavia restores mitochondrial energy 
metabolism gene expression and suppresses cardiac 
fibrosis in the border zone of the infarcted heart. 
Life Sci. 141, 170–178 (2015).
170. Andersson, D. C. et al. Mitochondrial production of 
reactive oxygen species contributes to the β-adrenergic 
stimulation of mouse cardiomycytes. J. Physiol. 589, 
1791–1801 (2011).
171. Eirin, A. et al. Mitochondrial targeted peptides 
attenuate residual myocardial damage after 
reversal of experimental renovascular hypertension. 
J. Hypertens. 32, 154–165 (2014).
172. Sabbah, H. N. et al. Chronic therapy with elamipretide 
(MTP-131), a novel mitochondria-targeting peptide, 
improves left ventricular and mitochondrial function 
in dogs with advanced heart failure. Circ. Heart Fail. 
9, e002206 (2016).
173. Min, K. et al. Mitochondrial-targeted antioxidants 
protect skeletal muscle against immobilization-induced 
muscle atrophy. J. Appl. Physiol. 111, 1459–1466 
(2011).
174. Powers, S. K. et al. Mitochondria-targeted antioxidants 
protect against mechanical ventilation-induced 
diaphragm weakness. Crit. Care Med. 39, 1749–1759 
(2011).
175. Halestrap, A. P., Clarke, S. J. & Javadov, S. A. 
Mitochondrial permeability transition pore opening 
during myocardial reperfusion — a target for 
cardioprotection. Cardiovasc. Res. 61, 372–385 
(2004).
176. Halestrap, A. P. & Pasdois, P. The role of the 
mitochondrial permeability transition pore in heart 
disease. Biochim. Biophys. Acta 1787, 1402–1415 
(2009).
177. Kowaltowski, A. J., Castilho, R. F. & Vercesi, A. E. 
Mitochondrial permeability transition and oxidative 
stress. FEBS Lett. 495, 12–15 (2001).
178. Sharov, V. G., Todor, A., Khanal, S., Imai, M. 
& Sabbah, H. N. Cyclosporine A attenuates 
mitochondrial permeability transition and improves 
mitochondrial respiratory function in cardiomyocytes 
isolated from dogs with heart failure. J. Mol. Cell. 
Cardiol. 42, 150–158 (2007).
179. Sharov, V. G., Todor, A. V., Imai, M. & Sabbah, H. N. 
Inhibition of mitochondrial permeability transition 
pores by cyclosporine A improves cytochrome c oxidase 
function and increases rate of ATP synthesis in failing 
cardiomyocytes. Heart Fail. Rev. 10, 305–310 (2005).
180. Lu, X., Kwong, J. Q., Molkentin, J. D. & Bers, D. M. 
Individual cardiac mitochondria undergo rare transient 
permeability transition pore openings. Circ. Res. 118, 
834–841 (2016).
181. Baines, C. P. The molecular composition of the 
mitochondrial permeability transition pore. J. Mol. Cell. 
Cardiol. 46, 850–857 (2009).
182. Halestrap, A. P. What is the mitochondrial permeability 
transition pore? J. Mol. Cell. Cardiol. 46, 821–831 
(2009).
183. Baines, C. P. et al. Loss of cyclophilin D reveals a critical 
role for mitochondrial permeability transition in cell 
death. Nature 434, 658–662 (2005).
184. Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J. 
& Molkentin, J. D. Voltage-dependent anion channels 
are dispensable for mitochondrial-dependent cell 
death. Nat. Cell Biol. 9, 550–555 (2007).
185. Kokoszka, J. E. et al. The ADP/ATP translocator is not 
essential for the mitochondrial permeability transition 
pore. Nature 427, 461–465 (2004).
186. Giorgio, V. et al. Dimers of mitochondrial ATP synthase 
form the permeability transition pore. Proc. Natl Acad. 
Sci. USA 110, 5887–5892 (2013).
187. Carraro, M. et al. Channel formation by yeast F-ATP 
synthase and the role of dimerization in the 
mitochondrial permeability transition. J. Biol. Chem. 
289, 15980–15985 (2014).
188. Ghaffari, S., Kazemi, B., Toluey, M. & Sepehrvand, N. 
The effect of prethrombolytic cyclosporine-A injection on 
clinical outcome of acute anterior ST-elevation myocardial 
infarction. Cardiovasc. Ther. 31, e34–e39 (2013).
189. MITOCARE Study Group. Rationale and design of the 
‘MITOCARE’ Study: a phase II, multicenter, randomized, 
double-blind, placebo-controlled study to assess the 
safety and efficacy of TRO40303 for the reduction of 
reperfusion injury in patients undergoing percutaneous 
coronary intervention for acute myocardial infarction. 
Cardiology 123, 201–207 (2012).
190. Mewton, N. et al. Effect of cyclosporine on left 
ventricular remodeling after reperfused myocardial 
infarction. J. Am. Coll. Cardiol. 55, 1200–1205 (2010).
191. Piot, C. et al. Effect of cyclosporine on reperfusion injury 
in acute myocardial infarction. N. Engl. J. Med. 359, 
473–481 (2008).
192. Naesens, M., Kuypers, D. R. & Sarwal, M. Calcineurin 
inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 
4, 481–508 (2009).
193. Tabara, L. C. et al. Mitochondria-targeted therapies for 
acute kidney injury. Expert Rev. Mol. Med. 16, e13 
(2014).
194. Hiemstra, J. A. et al. A new twist on an old idea part 2: 
cyclosporine preserves normal mitochondrial but not 
cardiomyocyte function in mini-swine with compensated 
heart failure. Physiol. Rep. 2, e12050 (2014).
195. Bayeva, M., Sawicki, K. T., Butler, J., Gheorghiade, M. 
& Ardehali, H. Molecular and cellular basis of viable 
dysfunctional myocardium. Circ. Heart Fail. 7,  
680–691 (2014).
196. Sohn, Y. S., Breuer, W., Munnich, A. & Cabantchik, Z. I. 
Redistribution of accumulated cell iron: a modality 
of chelation with therapeutic implications. Blood 111, 
1690–1699 (2008).
C O N S E N S U S  S TAT E M E N T
12 | ADVANCE ONLINE PUBLICATION www.nature.com/nrcardio
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
197. O’Rourke, B. et al. Mechanisms of altered excitation−
contraction coupling in canine tachycardia-induced 
heart failure, I: experimental studies. Circ. Res. 84, 
562–570 (1999).
198. Wilson, L. D. et al. Heart failure enhances susceptibility 
to arrhythmogenic cardiac alternans. Heart Rhythm 6, 
251–259 (2009).
199. Brown, D. A. & Cascio, W. E. ‘Leaky’ ryanodine 
receptors and sudden cardiac death. Cardiovasc. Res. 
84, 343–344 (2009).
200. Brown, D. A. & O’Rourke, B. Cardiac mitochondria and 
arrhythmias. Cardiovasc. Res. 88, 241–249 (2010).
201. Kosmala, W. et al. Effect of If-channel inhibition on 
hemodynamic status and exercise tolerance in heart 
failure with preserved ejection fraction: a randomized 
trial. J. Am. Coll. Cardiol. 62, 1330–1338 (2013).
202. Gorski, P. A., Ceholski, D. K. & Hajjar, R. J. Altered 
myocardial calcium cycling and energetics in heart 
failure — a rational approach for disease treatment. 
Cell. Metab. 21, 183–194 (2015).
203. Kawase, Y. & Hajjar, R. J. The cardiac sarcoplasmic/
endoplasmic reticulum calcium ATPase: a potent target 
for cardiovascular diseases. Nat. Clin. Pract. 
Cardiovasc. Med. 5, 554–565 (2008).
204. Kho, C., Lee, A. & Hajjar, R. J. Altered sarcoplasmic 
reticulum calcium cycling — targets for heart failure 
therapy. Nat. Rev. Cardiol. 9, 717–733 (2012).
205. Gong, H. B., Wang, L., Lv, Q. & Wang, J. Improved 
systolic function of rat cardiocytes during heart failure 
by overexpression of SERCA2a. Eur. Rev. Med. 
Pharmacol. Sci. 20, 1590–1596 (2016).
206. Mattila, M., Koskenvuo, J., Soderstrom, M., Eerola, K. 
& Savontaus, M. Intramyocardial injection of SERCA2a-
expressing lentivirus improves myocardial function 
in doxorubicin-induced heart failure. J. Gene Med. 
18, 124–133 (2016).
207. Greenberg, B. et al. Calcium upregulation by 
percutaneous administration of gene therapy in 
patients with cardiac disease (CUPID 2): a randomised, 
multinational, double-blind, placebo-controlled, 
phase 2b trial. Lancet 387, 1178–1186 (2016).
208. Belevych, A. E. et al. Redox modification of ryanodine 
receptors underlies calcium alternans in a canine 
model of sudden cardiac death. Cardiovasc. Res. 84, 
387–395 (2009).
209. Despa, S., Islam, M. A., Weber, C. R., Pogwizd, S. M. 
& Bers, D. M. Intracellular Na+ concentration is 
elevated in heart failure but Na/K pump function 
is unchanged. Circulation 105, 2543–2548 (2002).
210. Pieske, B. & Houser, S. R. [Na+]i handling in the failing 
human heart. Cardiovasc. Res. 57, 874–886 (2003).
211. Pieske, B., Houser, S. R., Hasenfuss, G. & Bers, D. M. 
Sodium and the heart: a hidden key factor in cardiac 
regulation. Cardiovasc. Res. 57, 871–872 (2003).
212. Pieske, B. et al. Rate dependence of [Na+]i and 
contractility in nonfailing and failing human 
myocardium. Circulation 106, 447–453 (2002).
213. Griffiths, E. J. Mitochondrial calcium transport in the 
heart: physiological and pathological roles. J. Mol. Cell. 
Cardiol. 46, 789–803 (2009).
214. Maack, C. et al. Elevated cytosolic Na+ decreases 
mitochondrial Ca2+ uptake during excitation-
contraction coupling and impairs energetic adaptation 
in cardiac myocytes. Circ. Res. 99, 172–182 (2006).
215. Palty, R. et al. NCLX is an essential component of 
mitochondrial Na+/Ca2+ exchange. Proc. Natl Acad. 
Sci. USA 107, 436–441 (2010).
216. Nicolau, S. M. et al. Mitochondrial Na+/Ca2+-exchanger 
blocker CGP37157 protects against chromaffin cell 
death elicited by veratridine. J. Pharmacol. Exp. Ther. 
330, 844–854 (2009).
217. Liu, T., Brown, D. A. & O’Rourke, B. Role of 
mitochondrial dysfunction in cardiac glycoside toxicity. 
J. Mol. Cell. Cardiol. 49, 728–736 (2010).
218. Primessnig, U. et al. Novel pathomechanisms of 
cardiomyocyte dysfunction in a model of heart failure 
with preserved ejection fraction. Eur. J. Heart Fail. 18, 
987–997 (2016).
219. Mamidi, R., Gresham, K. S., Li, A., dos Remedios, C. G. 
& Stelzer, J. E. Molecular effects of the myosin activator 
omecamtiv mecarbil on contractile properties of 
skinned myocardium lacking cardiac myosin binding 
protein-C. J. Mol. Cell. Cardiol. 85, 262–272 (2015).
220. Malik, F. I. et al. Cardiac myosin activation: a potential 
therapeutic approach for systolic heart failure. Science 
331, 1439–1443 (2011).
221. Cleland, J. G. et al. The effects of the cardiac myosin 
activator, omecamtiv mecarbil, on cardiac function 
in systolic heart failure: a double-blind, placebo-
controlled, crossover, dose-ranging phase 2 trial. 
Lancet 378, 676–683 (2011).
222. Greenberg, B. H. et al. Safety and tolerability of 
omecamtiv mecarbil during exercise in patients with 
ischemic cardiomyopathy and angina. JACC Heart Fail. 
3, 22–29 (2015).
223. Teerlink, J. R. et al. Acute treatment with omecamtiv 
mecarbil to increase contractility in acute heart failure: 
the ATOMIC-AHF study. J. Am. Coll. Cardiol. 67,  
1444–1455 (2016).
224. Teerlink, J. R. et al. Chronic oral study of myosin 
activation to increase contractility in heart failure 
(COSMIC-HF): final results from a double-blind, 
randomized, placebo-controlled, multicenter study 
[abstract]. Presented at American Heart Association 
Scientific Sessions 2015.
225. Moin, D. S., Sackheim, J., Hamo, C. E. & Butler, J. 
Cardiac myosin activators in systolic heart failure: more 
friend than foe? Curr. Cardiol. Rep. 18, 100 (2016).
226. Bakkehaug, J. P. et al. Myosin activator omecamtiv 
mecarbil increases myocardial oxygen consumption and 
impairs cardiac efficiency mediated by resting myosin 
ATPase activity. Circ. Heart Fail. 8, 766–775 (2015).
227. Nagy, L. et al. The novel cardiac myosin activator 
omecamtiv mecarbil increases the calcium sensitivity 
of force production in isolated cardiomyocytes and 
skeletal muscle fibres of the rat. Br. J. Pharmacol. 
http://dx.doi.org/10.1111/bph.13235 (2015).
228. Phan, T. T. et al. Heart failure with preserved ejection 
fraction is characterized by dynamic impairment of 
active relaxation and contraction of the left ventricle 
on exercise and associated with myocardial energy 
deficiency. J. Am. Coll. Cardiol. 54, 402–409 (2009).
229. Esposito, A. et al. Impaired left ventricular energy 
metabolism in patients with hypertrophic 
cardiomyopathy is related to the extension of fibrosis 
at delayed gadolinium-enhanced magnetic resonance 
imaging. Heart 95, 228–233 (2009).
230. Smith, C. S., Bottomley, P. A., Schulman, S. P., 
Gerstenblith, G. & Weiss, R. G. Altered creatine kinase 
adenosine triphosphate kinetics in failing hypertrophied 
human myocardium. Circulation 114, 1151–1158 
(2006).
231. Weiss, R. G., Gerstenblith, G. & Bottomley, P. A. ATP 
flux through creatine kinase in the normal, stressed, 
and failing human heart. Proc. Natl Acad. Sci. USA 
102, 808–813 (2005).
232. Crilley, J. G. et al. Hypertrophic cardiomyopathy due to 
sarcomeric gene mutations is characterized by impaired 
energy metabolism irrespective of the degree of 
hypertrophy. J. Am. Coll. Cardiol. 41, 1776–1782 
(2003).
233. Beer, M. et al. Absolute concentrations of high-energy 
phosphate metabolites in normal, hypertrophied, and 
failing human myocardium measured noninvasively with 
31P-SLOOP magnetic resonance spectroscopy. J. Am. 
Coll. Cardiol. 40, 1267–1274 (2002).
234. Beer, M. et al. [Cardiac energy metabolism in heart 
valve diseases with 31P MR spectroscopy [German]. 
Radiologe 40, 162–167 (2000).
235. Lamb, H. J. et al. Diastolic dysfunction in hypertensive 
heart disease is associated with altered myocardial 
metabolism. Circulation 99, 2261–2267 (1999).
236. Conway, M. A., Bottomley, P. A., Ouwerkerk, R., 
Radda, G. K. & Rajagopalan, B. Mitral regurgitation: 
impaired systolic function, eccentric hypertrophy, and 
increased severity are linked to lower phosphocreatine/
ATP ratios in humans. Circulation 97, 1716–1723 
(1998).
237. Jung, W. I. et al. 31P NMR spectroscopy detects 
metabolic abnormalities in asymptomatic patients 
with hypertrophic cardiomyopathy. Circulation 97, 
2536–2542 (1998).
238. Starling, R. C., Hammer, D. F. & Altschuld, R. A. Human 
myocardial ATP content and in vivo contractile function. 
Mol. Cell. Biochem. 180, 171–177 (1998).
239. Neubauer, S. et al. Cardiac high-energy phosphate 
metabolism in patients with aortic valve disease 
assessed by 31P-magnetic resonance spectroscopy. 
J. Investig. Med. 45, 453–462 (1997).
240. Neubauer, S. et al. Contributions of 31P-magnetic 
resonance spectroscopy to the understanding of dilated 
heart muscle disease. Eur. Heart J. 16 (Suppl. O),  
115–118 (1995).
241. Yabe, T., Mitsunami, K., Inubushi, T. & Kinoshita, M. 
Quantitative measurements of cardiac phosphorus 
metabolites in coronary artery disease by 31P magnetic 
resonance spectroscopy. Circulation 92, 15–23 (1995).
242. Yabe, T. et al. Detection of myocardial ischemia by 31P 
magnetic resonance spectroscopy during handgrip 
exercise. Circulation 89, 1709–1716 (1994).
243. Sakuma, H. et al. 31P MR spectroscopy in hypertrophic 
cardiomyopathy: comparison with Tl-201 myocardial 
perfusion imaging. Am. Heart J. 125, 1323–1328 
(1993).
244. Schaefer, S. et al. Metabolic response of the human 
heart to inotropic stimulation: in vivo phosphorus-31 
studies of normal and cardiomyopathic myocardium. 
Magn. Reson. Med. 25, 260–272 (1992).
245. de Roos, A. et al. Cardiac metabolism in patients with 
dilated and hypertrophic cardiomyopathy: assessment 
with proton-decoupled P-31 MR spectroscopy. J. Magn. 
Reson. Imaging 2, 711–719 (1992).
246. Neubauer, S. et al. 31P magnetic resonance 
spectroscopy in dilated cardiomyopathy and coronary 
artery disease. Altered cardiac high-energy 
phosphate metabolism in heart failure. Circulation 86,  
1810–1818 (1992).
247. Regitz, V. & Fleck, E. Myocardial adenine nucleotide 
concentrations and myocardial norepinephrine content 
in patients with heart failure secondary to idiopathic 
dilated or ischemic cardiomyopathy. Am. J. Cardiol. 69, 
1574–1580 (1992).
248. Conway, M. A. et al. Detection of low phosphocreatine 
to ATP ratio in failing hypertrophied human 
myocardium by 31P magnetic resonance spectroscopy. 
Lancet 338, 973–976 (1991).
249. Hardy, C. J., Weiss, R. G., Bottomley, P. A. 
& Gerstenblith, G. Altered myocardial high-energy 
phosphate metabolites in patients with dilated 
cardiomyopathy. Am. Heart J. 122, 795–801 (1991).
250. Schaefer, S. et al. In vivo phosphorus-31 spectroscopic 
imaging in patients with global myocardial disease. 
Am. J. Cardiol. 65, 1154–1161 (1990).
Acknowledgements
The roundtable discussion in Stresa, Italy, was organized by 
Logica Med LLC and funded by an unrestricted grant from 
Stealth BioTherapeutics. We thank Fumiko Inoue (Logica 
Med) for her help in organizing the roundtable meeting. The 
authors also acknowledge BioCentric, Inc. for their assistance 
with developing previous versions of the manuscript Figures. 
D.A.B. has received research grants from the NIH (NHLBI 
R01 HL123647 and R15 HL122922) and Stealth 
BioTherapeutics. B.L.S. is supported by research grants from 
the NIH (NIA R01 AG049762, NHLBI R01 HL131458, 
R01HL126928, and R01HL107715) and Stealth 
BioTherapeutics. S.R.S. is supported by grants from the NIH 
(R01 HL123647, R15 HL122922, and R01 AT008375). 
J.B.has received research support from the NIH and the 
European Union. A.A.V. is supported by a grant from the 
European Commission (FP7-242209-BIOSTAT-CHF).
Author contributions
D.A.B. wrote the manuscript, and all authors reviewed and 
edited it before submission.
Competing interests statement
D.A.B. has received consulting income from Stealth 
BioTherapeutics. J.G.F.C. reports consultation with Amgen, 
Biotronik, GSK, Medtronic, Novartis, Servier, Sorin, and 
Stealth BioTherapeutics. W.S.C. is a consultant to BMS, 
Cardioxyl, Johnson & Johnson, Mast, Merck, and Novartis. 
J.B. is a consultant to Amgen, Bayer, Boehringer Ingelheim, 
Cardiocell, Celladon, Novartis, Relypsa, Trevena, Z Pharma, 
and Zensun. A.A.V. has received consultancy fees and/or 
research grants from Alere, Amgen, Bayer, Boehringer, 
Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, 
Servier, Singulex, Sphingotec, Trevena, Vifor, and ZS 
Pharma. B.Pieske reports speaker’s bureau and/or advisory/
steering committee honoraria from Abbott Vascular, 
AstraZeneca, Bayer Healthcare, Novartis Pharma, Servier, 
and Stealth BioTherapeutics. M.G. has been a consultant for 
Abbott Laboratories, Astellas, AstraZeneca, Bayer 
HealthCare, CorThera, Cytokinetics, DebioPharm, 
Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Johnson 
& Johnson, Medtronic, Merck, Novartis Pharma, Otsuka 
Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, 
Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, 
Solvay Pharmaceuticals, Takeda Pharmaceutical, and 
Trevena Therapeutics. The other authors declare no 
competing interests.
This work is licensed under 
a   C r e a t i v e  C o m m o n s 
Attribution 4.0 International 
License. The images or other 
third party material in this 
article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is 
not included under the Creative Commons license, users will 
need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/.
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | CARDIOLOGY  ADVANCE ONLINE PUBLICATION | 13
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
